Tariquidar-related triazoles as potent, selective and stable inhibitors of ABCG2 (BCRP).


Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
01 Apr 2020
Historique:
received: 31 10 2019
revised: 04 02 2020
accepted: 06 02 2020
pubmed: 28 2 2020
medline: 5 11 2020
entrez: 28 2 2020
Statut: ppublish

Résumé

Tariquidar derivatives have been described as potent and selective ABCG2 inhibitors. However, their susceptibility to hydrolysis limits their applicability. The current study comprises the synthesis and characterization of novel tariquidar-related inhibitors, obtained by bioisosteric replacement of the labile moieties in our previous tariquidar analog UR-ME22-1 (9). CuAAC ("click" reaction) gave convenient access to a triazole core as a substitute for the labile amide group and the labile ester moiety was replaced by different acyl groups in a Sugasawa reaction. A stability assay proved the enhancement of the stability in blood plasma. Compounds UR-MB108 (57) and UR-MB136 (59) inhibited ABCG2 in a Hoechst 33342 transport assay with an IC

Identifiants

pubmed: 32105979
pii: S0223-5234(20)30100-8
doi: 10.1016/j.ejmech.2020.112133
pii:
doi:

Substances chimiques

ABCG2 protein, human 0
ATP Binding Cassette Transporter, Subfamily G, Member 2 0
Neoplasm Proteins 0
Quinolines 0
Triazoles 0
tariquidar J58862DTVD

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

112133

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Frauke Antoni (F)

Institute of Pharmacy, University of Regensburg, D-93040, Regensburg, Germany. Electronic address: frauke.antoni@ur.de.

Manuel Bause (M)

Institute of Organic Chemistry, University of Regensburg, D-93040, Regensburg, Germany.

Matthias Scholler (M)

Institute of Pharmacy, University of Regensburg, D-93040, Regensburg, Germany.

Stefanie Bauer (S)

Institute of Pharmacy, University of Regensburg, D-93040, Regensburg, Germany.

Simone A Stark (SA)

Institute of Organic Chemistry, University of Regensburg, D-93040, Regensburg, Germany.

Scott M Jackson (SM)

Institute of Molecular Biology and Biophysics, ETH Zürich, CH-8093, Zürich, Switzerland.

Ioannis Manolaridis (I)

Institute of Molecular Biology and Biophysics, ETH Zürich, CH-8093, Zürich, Switzerland.

Kaspar P Locher (KP)

Institute of Molecular Biology and Biophysics, ETH Zürich, CH-8093, Zürich, Switzerland.

Burkhard König (B)

Institute of Organic Chemistry, University of Regensburg, D-93040, Regensburg, Germany. Electronic address: burkhard.koenig@ur.de.

Armin Buschauer (A)

Institute of Pharmacy, University of Regensburg, D-93040, Regensburg, Germany.

Günther Bernhardt (G)

Institute of Pharmacy, University of Regensburg, D-93040, Regensburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH